PMC5937370_01
CSF analysis. (a) MGG stained cytospin preparation; (b) fluorescence in situ hybridization (FISH) with probes for 17p (normal); ((c) and (d)) flow cytometry: the plasma cells are CD38, 56, and 138 positive.
JO2018-3970169.003.jpg
PMC5937370_01_JO2018-3970169.003.jpg
fig3
With 3-month follow-up, he is alive and well, and his CSF that was previously full of plasma cells (Figure 3(a)) is now clear.
Treatments and responses. Allo: allogeneic stem cell transplantation; amp: amplification; ASCT: autologous stem cell transplantation; Bor: bortezomib; Car: carfilzomib; CI: cranial irradiation; CSF: cerebrospinal fluid; CTD: cyclophosphamide, thalidomide, and dexamethasone; CyBorDex: cyclophosphamide, bortezomib, and dexamethasone; Dara: daratumumab; del: deletion; DVd: daratumumab, bortezomib, and dexamethasone; flow: flow cytometry; hyperd: hyperdiploid; IFX: immunofixation; IRD: ixazomib, revlimid, and dexamethasone; IT: intrathecal chemotherapy; KTD: carfilzomib, thalidomide, and dexamethasone; LC: light chain; Len: lenalidomide; maint: maintenance; MPV: melphalan, prednisolone, and bortezomib; ND: not done; PACE: cisplatin, doxorubicin, cyclophosphamide, and etoposide; PAD: bortezomib, doxorubicin, and dexamethasone; PCL: plasma cell leukemia; PomD: pomalidomide and dexamethasone; RT: radiotherapy; T-CED: thalidomide, cyclophosphamide, etoposide, and dexamethasone; Thal: thalidomide; Thio: thiotepa; VAD: vincristine, doxorubicin, and dexamethasone; VRD: bortezomib, lenalidomide, and dexamethasone; VTD: bortezomib, thalidomide, and dexamethasone.
JO2018-3970169.004.jpg
PMC5937370_01_JO2018-3970169.004.jpg
fig4
Patients' characteristics including symptoms, treatments, and survival are shown in Table 1, treatment courses and responses to various treatment lines are depicted graphically in Figure 4, and progression-free survival and overall survival given in Figure 5.
Progression-free survival (PFS) and overall survival (OS).
JO2018-3970169.005.jpg
PMC5937370_01_JO2018-3970169.005.jpg
fig5
Patients' characteristics including symptoms, treatments, and survival are shown in Table 1, treatment courses and responses to various treatment lines are depicted graphically in Figure 4, and progression-free survival and overall survival given in Figure 5.